Drug-eluting stents: how long before surgery?

The single number most of us memorized is gone. The 2024 guideline replaced it with two, and which one applies depends on why the stent was placed rather than what kind of stent it is.

Reviewed and updated August 2026 · Written by Anastasia Jackson, DNAP, CRNA

Every clinical claim on this page is cited to its source below. How we source clinical content — and the corrections we have made, with what each one was and why it changed.

If you trained before 2016 you learned one year. If you trained after the focused update on dual antiplatelet therapy duration that year, you probably learned six months.¹⁴ Both were reasonable readings of the guidance at the time, and neither is the current answer. The 2024 perioperative guideline splits the question in two, and the split is not by stent generation or stent type. It is by the clinical problem that put the stent in.

What the 2024 guideline says

The 2024 multi-society guideline for perioperative cardiovascular management supersedes the 2014 document entirely.¹ These are its timing recommendations for patients with prior percutaneous coronary intervention facing noncardiac surgery.

Why the indication now drives the number

This is the conceptual shift worth internalizing. A patient stented after a myocardial infarction and a patient stented for stable angina can receive the identical stent, from the identical box, deployed by the identical operator — and carry meaningfully different perioperative risk afterward.

The stent is not the whole story. The plaque biology, the systemic inflammatory state, and the myocardium that was recently injured all travel with the patient into your operating room. The guideline’s split by indication is an acknowledgment that the risk being managed is not purely mechanical.

Where the numbers came from

Observational data does almost all of the work underneath these recommendations, which is why most of them are Class 2 rather than Class 1. Four cohorts are worth knowing in their own right, and they do not all point the same way.

The Ontario cohort: the shape of the risk curve

A population-based study of 8,116 patients who had major elective noncardiac surgery within ten years of receiving a coronary stent, compared against 341,350 surgical patients who had never been revascularized.³ The 30-day event rate — death, readmission for acute coronary syndrome, or repeat revascularization — traced a clear gradient.

One in five is not a subtle signal, and it is the single most persuasive number in this literature for not operating early. By six months the drug-eluting stent rate had fallen to a level approaching that of non-revascularized patients at intermediate risk. The authors concluded that the earliest optimal window for elective surgery was 46 to 180 days after a bare-metal stent, or beyond 180 days after a drug-eluting stent.³

The Veterans Affairs cohort: timing is not the main driver

A national retrospective cohort of 41,989 operations occurring within two years of stent placement, drawn from 124,844 stent implantations. Among 28,029 patients who had noncardiac surgery, there were 1,980 major adverse cardiac events, a rate of 4.7%.⁴

Time from stent to surgery was associated with events during the first six months and not beyond it. Stent type was not associated with events beyond six months at all — 5.1% for bare-metal, 4.3% for drug-eluting. But the more instructive finding was which variables carried the most weight.

An odds ratio compares the odds of an event between two groups; 1.0 means no difference, and higher means more common. The confidence interval is the range compatible with the data. What the table says is that whether the case was booked as an emergency mattered roughly twice as much as anything about the stent, and that the patient’s underlying cardiac disease outranked the calendar.

The same study included a case-control analysis of 284 matched pairs and found no association between stopping antiplatelet therapy and events — odds ratio 0.86 (95% CI 0.57–1.29).⁴ The authors argued directly that guideline emphasis on stent type and surgical timing should be reconsidered. A companion analysis from the same group quantified the increment surgery itself adds on top of having a stent: 3.1% versus 1.9% for the 30-day composite of myocardial infarction or revascularization, a risk difference of 1.3%, which was 3.5% immediately after stenting, fell to about 1% at six months, and then held flat out to two years.⁵ The 2024 guideline’s move away from stent type, and toward indication and patient risk, is partly a response to exactly this line of work.

The Danish cohort: the excess is early

Comparing 4,303 patients who had surgery within 12 months of a drug-eluting stent against 20,232 surgical patients with no ischemic heart disease found a clear excess: myocardial infarction 1.6% versus 0.2% (odds ratio 4.82), cardiac death 1.0% versus 0.2% (5.87). But all-cause mortality was not significantly different — 3.1% versus 2.7%, odds ratio 1.12 (0.91–1.38).⁶ Stratified by time from stent to surgery, only the first month carried a significant increase, which led the authors to conclude that surgery might reasonably be undertaken earlier than the guidelines of the day allowed.

That conclusion has not been adopted, and the reason is worth stating rather than glossing. These are registry comparisons against patients without coronary disease; they establish that the excess is concentrated early, not that the later intervals are unnecessary. The guideline writers responded by widening the time-sensitive category rather than by lowering the elective interval — the more conservative reading of the same data.

The contemporary picture, and it is less alarming

The newest of these is a Veterans Affairs surgical quality cohort covering operations from 2017 to 2021 — the second-generation drug-eluting stent era rather than the first. Among 334,828 operations, 2,297 patients had undergone percutaneous coronary intervention within two years. In 9,160 propensity-matched patients there was no difference in one-year major adverse cardiovascular events between those with and without a recent intervention (hazard ratio 1.04, 95% CI 0.96–1.17). All-cause death was lower in the stented group (0.83, 0.72–0.96), and repeat revascularization higher (1.88, 1.50–2.36).⁸

This does not repeal the early window — the mortality advantage did not extend to patients operated within a month of intervention, and the study was not designed to test the guideline thresholds. What it does say is that a patient with a stent placed a year ago and managed properly is not carrying the risk the older literature implies. The danger is concentrated at the front of the timeline, and this page keeps saying so because every cohort on it says so.

Who is at higher risk than the calendar suggests

Two patients can both be seven months out from a drug-eluting stent and not be equivalent. European Society of Cardiology guidance lists features that mark a patient as high risk for perioperative stent thrombosis regardless of where they sit on the timeline.^2,13

• History of recurrent myocardial infarction
• Prior stent thrombosis while on antiplatelet therapy
• Left ventricular ejection fraction below 40%
• Poorly controlled diabetes
• Severely impaired renal function, or on hemodialysis
• Recent complex intervention — severely calcified lesion, left main intervention, chronic total occlusion, bifurcation or crush technique, bypass graft intervention
• Stent malapposition or residual dissection

These are the patients for whom the multidisciplinary conversation is not a formality. They are also the patients in whom a cardiologist may want the surgery pushed past the guideline minimum rather than to it.

When the surgery cannot wait

Most of the real-world difficulty sits here: the cancer resection at four months, the fracture, the symptomatic hernia. The guideline’s structure gives you a workable sequence.

Continue aspirin

In patients with prior percutaneous coronary intervention undergoing noncardiac surgery, continuing aspirin at 75 to 100 mg is recommended where possible (Class 1, B-R). P2Y12 receptor monotherapy may be considered instead if surgical bleeding risk is acceptable or aspirin is not tolerated.¹

This recommendation is often challenged with the POISE-2 trial, which randomized 10,010 patients having noncardiac surgery to perioperative aspirin or placebo and found no reduction in death or nonfatal myocardial infarction — 7.0% versus 7.1%, hazard ratio 0.99 (95% CI 0.86–1.15) — alongside more major bleeding, 4.6% versus 3.8%, hazard ratio 1.23 (1.01–1.49).⁹ The reason POISE-2 does not overturn the stent recommendation is that it largely was not a study of recently stented patients: it excluded bare-metal stents placed within six weeks and drug-eluting stents placed within one year.¹⁰ Generalizing it to the four-month drug-eluting stent is exactly the extrapolation its own investigators cautioned against.

Continue dual antiplatelet therapy for the very recent stent

For time-sensitive surgery within 30 days of a bare-metal stent, or within 3 months of a drug-eluting stent, dual antiplatelet therapy should be continued unless bleeding risk outweighs the benefit of preventing stent thrombosis (Class 1, B-NR).¹ This is the situation where the surgical team is being asked to accept a bleeding penalty, and it should be an explicit conversation rather than an assumption made in either direction.

The European framing of the same question is worth knowing because it is expressed differently: for time-sensitive surgery after an elective intervention, the European threshold is a minimum of one month of completed dual antiplatelet therapy rather than three months elapsed (Class I).¹³ It is a drug-exposure threshold, not a calendar one, and for a patient whose therapy was interrupted early the two can differ substantially.

If the P2Y12 inhibitor must stop

The European intervals differ slightly on ticagrelor, at 3 to 5 days, and are otherwise the same.^2,13 For the neuraxial and interventional pain thresholds, which are a separate set of numbers from a separate society and are frequently confused with these, see clopidogrel hold time before neuraxial and pain procedures.

Bridging

Routine bridging with intravenous antiplatelet therapy is not a default pathway. The 2024 guideline positions it narrowly: in selected patients after percutaneous coronary intervention who are at high thrombotic risk, perioperative bridging may be considered when they are less than 6 months from a drug-eluting stent or less than 30 days from a bare-metal stent and the surgery cannot be deferred.¹

What this looks like in practice

Frequently asked questions

How long should elective surgery be delayed after a drug-eluting stent?

Under the 2024 perioperative guideline, at least 12 months if the stent was placed for acute coronary syndrome, and at least 6 months if it was placed for chronic coronary disease, where elective surgery would require interrupting at least one antiplatelet agent.¹ Twelve months may also be appropriate for complex intervention such as bifurcation stents, long stent lengths, or multivessel disease.²

Does the reason the stent was placed really change the waiting period?

Yes, and that is the main change from earlier guidance. The same stent carries different perioperative risk depending on why it went in, and the guideline now sets two different intervals on that basis.¹ The commonly quoted threefold difference in postoperative infarction comes from a congress abstract rather than a published paper, and its own stratification put the excess in the first month.⁷

What if the surgery cannot wait 6 or 12 months?

Time-sensitive surgery may be considered at 3 months or more after a drug-eluting stent when the risk of further delay outweighs the cardiac risk.^1,2 Within 30 days of a bare-metal stent or 3 months of a drug-eluting stent, dual antiplatelet therapy should be continued unless bleeding risk outweighs the benefit (Class 1). Timing and antiplatelet management should be set by a multidisciplinary team with shared decision-making rather than by any one service.¹

Should aspirin be continued through surgery in a patient with a stent?

Yes where possible. Continuing aspirin at 75 to 100 mg is a Class 1 recommendation in patients with prior percutaneous coronary intervention.¹ The POISE-2 trial found no benefit and more bleeding with perioperative aspirin, but it excluded recently stented patients, so it does not override this recommendation — and its prior-intervention subgroup pointed the other way.^9,10

How long before surgery should clopidogrel, ticagrelor, or prasugrel be stopped?

If a P2Y12 inhibitor must be held: prasugrel 7 days, clopidogrel 5 days, ticagrelor 3 days.² Ticagrelor is the only reversible agent of the three. Restart as soon as it is safe to do so after surgery; no guideline specifies an hour.^1,14

Is bridging with intravenous antiplatelet therapy recommended?

Not routinely. It may be considered in selected high-thrombotic-risk patients who are under 6 months from a drug-eluting stent or under 30 days from a bare-metal stent and whose surgery cannot be deferred.¹ The trial usually cited for it used a platelet-reactivity endpoint in cardiac surgery, so it is a decision made jointly with cardiology rather than a pathway with outcome evidence behind it.¹¹

Is the waiting period different for a bare-metal stent?

Yes, and much shorter — at least 30 days, with balloon angioplasty alone requiring a minimum of 14.¹ Bare-metal stents are now uncommon in contemporary practice, and the older logic that made them attractive before planned surgery — a shorter mandatory antiplatelet commitment — has not held up. Where intervention is indicated before noncardiac surgery, current-generation drug-eluting stents are preferred over bare-metal stents or balloon angioplasty.¹³

Does stent type matter more than how long it has been?

Beyond six months, neither appears to be the dominant variable. In a cohort of 41,989 operations, event rates were 5.1% for bare-metal and 4.3% for drug-eluting stents, with no association between stent type and events beyond six months, and timing ranked fifth of twelve variables in explanatory importance. The strongest predictors were nonelective admission (odds ratio 4.77), myocardial infarction in the preceding six months (2.63), and a Revised Cardiac Risk Index above 2 (2.13).⁴

References

1. Thompson A, Fleischmann KE, Smilowitz NR, et al. 2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery. Circulation. 2024;150(19):e351–e442. doi:10.1161/CIR.0000000000001285. Also published as J Am Coll Cardiol. 2024;84(19):1869–1969. PMID 39320289. Supersedes the 2014 guideline. Source of every interval and class in the table above, the 30-day harm statement, the aspirin and dual therapy recommendations, the multidisciplinary recommendation, and the position on bridging.
2. Cohn SL. 2024 ACC/AHA guideline on perioperative cardiovascular management before noncardiac surgery: what’s new? Cleve Clin J Med. 2025;92(4):213–219. doi:10.3949/ccjm.92a.24125. Source of the revised urgency definitions, the complex-anatomy 12-month note, the antiplatelet hold intervals, and the European high-risk feature list as summarized there.
3. Wijeysundera DN, Wijeysundera HC, Yun L, Wąsowicz M, Beattie WS, Velianou JL, Ko DT. Risk of elective major noncardiac surgery after coronary stent insertion: a population-based study. Circulation. 2012;126(11):1355–1362. doi:10.1161/CIRCULATIONAHA.112.102715. PMID 22893606. 8,116 stented patients versus 341,350 nonrevascularized; overall 30-day events 2.1%; under 45 days 20.0% drug-eluting and 6.7% bare-metal; 45–180 days bare-metal 2.6%; beyond 180 days drug-eluting 1.2%.
4. Hawn MT, Graham LA, Richman JS, Itani KMF, Henderson WG, Maddox TM. Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents. JAMA. 2013;310(14):1462–1472. doi:10.1001/jama.2013.278787. PMID 24101118. 28,029 operations, 1,980 events (4.7%). Nonelective admission adjusted OR 4.77 (4.07–5.59); myocardial infarction in the preceding 6 months 2.63 (2.32–2.98); Revised Cardiac Risk Index above 2 2.13 (1.85–2.44). Drug-eluting stent 0.91 (0.83–1.01), not significant. Case-control of 284 matched pairs, antiplatelet cessation OR 0.86 (0.57–1.29).
5. Holcomb CN, Graham LA, Richman JS, Rhyne RR, Itani KMF, Maddox TM, Hawn MT. The incremental risk of noncardiac surgery on adverse cardiac events following coronary stenting. J Am Coll Cardiol. 2014;64(25):2730–2739. doi:10.1016/j.jacc.2014.09.072. PMID 25541124. 20,590 surgical patients matched to 41,180 nonsurgical; composite 3.1% versus 1.9%, risk difference 1.3% (1.0–1.5); incremental risk 3.5% immediately after stenting, 1% at 6 months, stable to 24 months.
6. Egholm G, Kristensen SD, Thim T, et al. Risk associated with surgery within 12 months after coronary drug-eluting stent implantation. J Am Coll Cardiol. 2016;68(24):2622–2632. doi:10.1016/j.jacc.2016.09.967. PMID 27978946. 4,303 stented surgical patients versus 20,232 without ischemic heart disease. Myocardial infarction 1.6% versus 0.2% (OR 4.82, 3.25–7.16); cardiac death 1.0% versus 0.2% (OR 5.87, 3.60–9.58); all-cause mortality 3.1% versus 2.7% (OR 1.12, 0.91–1.38, not significant). Only the first month significant on stratification.
7. Egholm G, Thim T, Olesen KKW, Madsen M, Jensen SE, Jensen LO, Bøtker HE, Kristensen SD, Maeng M. Risk of adverse cardiac events in patients undergoing surgery after coronary drug-eluting stent implantation for acute coronary syndrome and stable angina pectoris. Eur Heart J. 2017;38(Suppl 1):ehx502.P2330. Congress abstract; not published in full. Postoperative myocardial infarction 1.9% versus 0.6%, OR 3.21 (1.76–5.83), adjusted 2.50 (1.35–4.61); first month 8.6% versus 2.7%, OR 2.80 (1.26–6.20); months 1–12 0.6% versus 0.3%, OR 2.05 (0.77–5.50), not significant; all-cause mortality adjusted OR 0.90 (0.64–1.26). This is the origin of the “threefold” figure quoted elsewhere for the acute coronary syndrome indication.
8. Butala NM, et al. Outcomes after noncardiac surgery performed within 2 years of percutaneous coronary intervention. J Am Heart Assoc. 2025;14(6):e038807. doi:10.1161/JAHA.124.038807. PMID 40079295. 334,828 operations 2017–2021; 2,297 (0.68%) with intervention within 2 years. Among 9,160 propensity-matched patients, no difference in 1-year major adverse cardiovascular events (HR 1.04, 0.96–1.17); lower all-cause death (0.83, 0.72–0.96); higher revascularization (1.88, 1.50–2.36).
9. Devereaux PJ, Mrkobrada M, Sessler DI, et al; POISE-2 Investigators. Aspirin in patients undergoing noncardiac surgery. N Engl J Med. 2014;370(16):1494–1503. doi:10.1056/NEJMoa1401105. PMID 24679062. 10,010 patients; death or nonfatal myocardial infarction 7.0% versus 7.1%, hazard ratio 0.99 (0.86–1.15); major bleeding 4.6% versus 3.8%, hazard ratio 1.23 (1.01–1.49).
10. Graham MM, Sessler DI, Parlow JL, et al. Aspirin in patients with previous percutaneous coronary intervention undergoing noncardiac surgery. Ann Intern Med. 2018;168(4):237–244. doi:10.7326/M17-2341. PMID 29132159. Non-prespecified subgroup of 470 within POISE-2. Death or nonfatal myocardial infarction absolute risk reduction 5.5% (0.4–10.5), hazard ratio 0.50 (0.26–0.95); myocardial infarction 5.9% (1.0–10.8), 0.44 (0.22–0.87). Also the source for POISE-2’s exclusion of bare-metal stents within 6 weeks and drug-eluting stents within 1 year.
11. Angiolillo DJ, Firstenberg MS, Price MJ, et al; BRIDGE Investigators. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA. 2012;307(3):265–274. doi:10.1001/jama.2011.2002. PMID 22253393. 210 patients awaiting coronary artery bypass grafting. Primary endpoint was platelet reactivity: below 240 reaction units in 98.8% versus 19.0%, relative risk 5.2 (3.3–8.1). Cardiac surgery and a surrogate endpoint, both of which limit what it can be cited for.
12. Kałuża GL, Joseph J, Lee JR, Raizner ME, Raizner AE. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol. 2000;35(5):1288–1294. doi:10.1016/s0735-1097(00)00521-0. PMID 10758971. 40 consecutive patients operated within six weeks of stenting: 7 myocardial infarctions, 11 major bleeding episodes, 8 deaths; all deaths and infarctions in patients operated fewer than 14 days from stenting.
13. Halvorsen S, Mehilli J, Cassese S, et al. 2022 ESC guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J. 2022;43(39):3826–3924. doi:10.1093/eurheartj/ehac270. PMID 36017553. Six months after elective intervention and twelve after acute coronary syndrome, both Class I; a minimum of one month of completed dual antiplatelet therapy before time-sensitive surgery after elective intervention, Class I; P2Y12 stop intervals of ticagrelor 3–5 days, clopidogrel 5 days, prasugrel 7 days; the high-thrombotic-risk feature list; and the preference for current-generation drug-eluting stents when intervention is indicated before surgery.
14. Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. Circulation. 2016;134(10):e123–e155. doi:10.1161/CIR.0000000000000404. PMID 27026020. The document that moved the drug-eluting stent interval from 12 months to 6, and the source of the rule that aspirin is continued and the P2Y12 inhibitor restarted as soon as possible after surgery.